Next Phase Newsletter

A global investor, headquartered in Western Europe with no geographical restrictions, is actively seeking new investment opportunities. The firm is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic diseases. The firm makes selective investments in newly founded or early-stage companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards, and it can invest $25-30M over the lifetime of the companies. Currently, the firm is raising its fourth fund which in addition to its core strategy to invest in early stage companies, will also be used to invest in late stage financings, cross-over financings, IPO’s, and listed stock. These companies can either be portfolio companies or external companies.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Projects will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

At its core, the firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of its portfolio companies. To this end, the firm has several experts in oncology and genetic diseases, intellectual property, and drug development on the investment team which are available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Singapore, with an additional office in the US makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and digital health. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

With multiple offices throughout the US, a new business unit within a large corporation is focused on improving the quality, affordability and equity of employer-sponsored health care. This new investment arm is investing from the corporate’s balance sheet in early-stage and advanced health companies that offer accountable care and value-based solutions to employers and employees.

The firm’s “sweet spot” is in Series B and beyond. While the organization primarily deploys growth equity capital, it can consider making investments into earlier stage companies. The firm can invest in, and will consider opportunities outside of the U.S. market, but these opportunities must be focused on the employer-sponsored insurance market in the U.S.

Within healthcare, the firm invests primarily in accountable care-centered solutions and integrated disease management programs. The firm’s core focus areas are care delivery, priority conditions, analytics & enablers of advanced medical care, and pharma services.

The firm is also focused on health solutions that can be implemented in a remote or at-home setting, reducing the burden of patients. In terms of stage of development, the firm expects to see customer traction and revenue generation taking place – companies who are still developing a working product that has yet to be implemented will generally be considered too early for investment.

The firm seeks to invest in companies that have established substantial validation on their product/technology. The firm has board representation with each of the companies it has invested in and has typically served as a syndicate partner to lead investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A women-led venture capital is raising a new venture fund and is looking to invest in life science companies that address women’s health between Seed to Series A in Europe, the UK, and Israel, eventually scaling to the U.S as well. Typical check sizes range anywhere between £500k-1M for the first round and will double down up to £2M in Series A. The firm is open to acting as a lead investor for smaller rounds, however they are currently co-investing especially as they start to invest in the U.S.

The firm is open to any life science sector including therapeutics, diagnostics, medical devices, digital health, etc. in the clinical stage as long as the company addresses women’s health. This includes innovations that solely, disproportionately, and/or differently affect women, such as menopause, autoimmune diseases, and heart disease. The firm is open to anywhere from therapeutics and genomics to consumer products. The firm requires to see clinical data and efficacy in the technology. In terms of medical devices, the firm is open to all classes. The only exception that the firm does not invest in is pharmaceuticals.

The firm does not have specific team requirements, however the firm will take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.